Lexeo Therapeutics, Inc.

Lexeo Therapeutics is a clinical-stage genetic medicine company developing AAV-based gene therapies for hereditary and acquired cardiac and neurological diseases. The company's pipeline focuses on rare conditions with limited treatment options, including Friedreich ataxia cardiomyopathy, arrhythmogenic cardiomyopathy (ACM), hypertrophic cardiomyopathy, and APOE4-associated Alzheimer's disease. Lead candidates LX2006 and LX2020 are currently in phase 1/2 clinical trials, while LX2021 and LX2022 remain in preclinical development. LX1001, targeting Alzheimer's disease, has completed phase 1/2 testing.

The company operates through research and development and clinical trial activities. Lexeo has established collaborative relationships with Cornell University, including license agreements for its Alzheimer's program and rights to clinical data from ongoing investigator-initiated trials in Friedreich ataxia cardiomyopathy. These partnerships provide access to preclinical research capabilities and clinical development infrastructure.

Lexeo operates with a team of 61 full-time employees and is headquartered in New York, New York. As a clinical-stage company, the firm does not currently generate product revenues and remains pre-commercialization, with operations concentrated in the United States.